John G. Clohessy

Apr 15, 2024 | nature.com | Fabin Dang |Lin Wang |Wenxue Li |Felipe Batalini |Jaymin Patel |John G. Clohessy | +4 more

AbstractInduced oncoproteins degradation provides an attractive anti-cancer modality. Activation of anaphase-promoting complex (APC/CCDH1) prevents cell-cycle entry by targeting crucial mitotic proteins for degradation. Phosphorylation of its co-activator CDH1 modulates the E3 ligase activity, but little is known about its regulation after phosphorylation and how to effectively harness APC/CCDH1 activity to treat cancer.